Obesity & Overweight
Worldwide adult obesity has more than doubled since 1990 — 16% of adults are now obese and 43% are overweight (including obesity, WHO 2022). Childhood obesity rose four-fold over the same window. The medical class of GLP-1 receptor agonists is reshaping treatment in wealthy countries while access remains negligible in the global south.
Key insights
The Americas and Pacific lead
US adult obesity was 40.3% in the latest measured data (2021-23) — among the highest in the OECD. Pacific Island nations (Nauru, Tonga, Samoa, Palau) exceed 50% for both sexes. The lowest rates remain in South and East Asia (India 4%, Vietnam 2%, Japan 4.5%) though all are rising. Mexico (36%) and Chile (34%) have caught up with Western Europe.
Child obesity is the fastest-rising indicator
Children and adolescents living with obesity rose from 31 million (1990) to 160 million (2022). Childhood obesity tracks into adulthood in roughly 80% of cases and substantially raises lifetime risk of diabetes, cardiovascular disease and several cancers. The WHO has set a target of no increase in childhood obesity by 2025 — that target has been missed in every region.
GLP-1 drugs change the trajectory in rich countries
Semaglutide, tirzepatide and successor molecules produce 15–20% weight loss in trials. A 2024 KFF poll found about 12% of US adults had ever used one. Cost ($10,000+/year at US list prices, with discounts since 2025) has limited use mainly to wealthy markets. Early models suggest these drugs could lower US obesity prevalence by 3–5 percentage points by 2030 if access expands.
Adult obesity prevalence — selected countries (latest available)
% of adults with BMI ≥ 30
Show data table
| % obese | |
|---|---|
| Nauru | 59 |
| USA | 40.3 |
| Saudi Arabia | 38.8 |
| Mexico | 36.1 |
| UK | 28 |
| Australia | 30.4 |
| Germany | 23.6 |
| Brazil | 22.1 |
| China | 8.1 |
| France | 21.6 |
| Japan | 4.5 |
| India | 4 |
Key Finding: Pacific Island nations dwarf the rest of the world; the US leads OECD; South/East Asia remain comparatively low but rising.
Adult obesity trend — major economies 1990–2023
% of adults with BMI ≥ 30
Show data table
| USA | UK | China | Brazil | |
|---|---|---|---|---|
| 1990 | 23 | 13 | 2 | 7 |
| 2000 | 31 | 21 | 3.5 | 11 |
| 2010 | 36 | 25 | 5 | 16 |
| 2015 | 40 | 27 | 6.5 | 18 |
| 2020 | 42 | 28 | 7.5 | 21 |
| 2023 | 40.3 | 28 | 8.1 | 22 |
Key Finding: US adult obesity rose from about 23% (1988-94) to 41.9% (2017-20), then 40.3% (2021-23), a change CDC does not treat as statistically significant. Other countries shown are still rising or flat; no large country has clearly reversed the trend.
Methodology & caveats
BMI thresholds and limitations
BMI = weight (kg) / height (m)². WHO classifies overweight as BMI ≥ 25 and obesity as BMI ≥ 30. The thresholds do not adjust for muscle mass, frame size or ethnicity — Asian populations face cardiometabolic risk at lower BMI, prompting some health authorities to use BMI ≥ 27.5 as the obesity cut-off for these groups.
Self-report vs measured
Self-reported height and weight systematically understate obesity — people round up height and down weight. Population estimates that rely on health-examination surveys (the US NHANES, UK Health Survey) are 3–5 percentage points higher than self-reported equivalents. Cross-country comparisons should use the same survey type.
Double burden
Many low and middle-income countries now face a 'double burden' — adult and childhood obesity rising even as stunting and micronutrient deficiency persist among the poorest. This is not paradoxical: cheap, energy-dense calories from sugar, refined grains and oils have become widely available while diets remain deficient in protein and micronutrients.
Why country comparisons wobble
WHO and NCD-RisC model prevalence from hundreds of measured surveys, while OECD figures mix measured data with self-report. The same country can differ by several points between the two, and many low-income estimates rest on a few urban surveys. Age-standardised and crude rates also diverge in ageing populations. Treat any single-year ranking as approximate. Children are classified using growth references, not a fixed BMI cut-off, so child obesity trends rely on which reference a study uses.
What would change the picture
The clearest test will be whether the US and other heavy users of GLP-1 drugs show measured falls in the next NHANES cycles, rather than in self-reported polls. Generic semaglutide is arriving in several markets as patents expire, and WHO has added GLP-1 drugs to its essential medicines work. In low-income countries, the main question is whether food policy can act before obesity becomes entrenched, as sugar taxes have started to in Mexico and the UK.
Cite this page
GlobeChart. “Obesity & Overweight.” Last updated 2026-10-31. https://globechart.com/health/obesity/
Please also credit the original publisher named under each chart: WHO Global Health Observatory, OECD Health Statistics; WHO Global Health Observatory, NCD-RisC. Spotted an error? Tell us.